Please login to the form below

Not currently logged in
Email:
Password:

Wyeth withdraws Pristiqs application

Wyeth Pharmaceuticals has withdrawn a marketing application for Pristiqs from the European Medicines Agency, it announced on March 12

Wyeth Pharmaceuticals has withdrawn a marketing application for Pristiqs from the European Medicines Agency (EMEA), it announced on March 12.

The EMEA's Committee for Medicinal Products for Human Use (CHMP) raised questions about the risk-benefit profile of Pristiqs (desvenlafaxine) as a treatment for menopausal vasomotor symptoms (hot flashes).

The company now intends to carry out further studies and continue the development of the drug as a potential treatment.

Dr Gary Stiles, executive vice president and chief medical officer of Wyeth Pharmaceuticals, said: "We believe that desvenlafaxine can provide women with a non-hormonal option to treat vasomotor symptoms, and Wyeth remains committed to developing the molecule for this indication."

"Some of the questions raised by the CHMP can be addressed with our planned clinical trails, including the 12 month study Wyeth is initiating with post-menopausal women early this year," he added.

The original European marketing authorisation was submitted on 4 October 2006 and Pristiqs was under CHMP review at the time Wyeth withdrew the application.

Details and scientific data about the trails will be made published in a question-and-answer document together with the withdrawal letter by the EMEA in due course.

12th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics